Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study

被引:12
作者
Stevens, Lena [1 ]
Brown, Zachary J. [1 ]
Zeh, Ryan [2 ]
Monsour, Christina [1 ]
Wells-Di Gregorio, Sharla [3 ]
Santry, Heena [1 ]
Ejaz, Aslam M. [1 ]
Pawlik, Timothy Michael [1 ]
Cloyd, Jordan M. [1 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Dept Surg, 410 W 10th Ave, Columbus, OH 43210 USA
[2] Univ Pittsburgh, Med Ctr, Dept Gen Surg, Pittsburgh, PA 15213 USA
[3] Ohio State Univ, Wexner Med Ctr, Ctr Palliat Care, Dept Psychiat, Columbus, OH 43210 USA
关键词
Pancreatic ductal adenocarcinoma; Neoadjuvant therapy; Patient experience; Patient-centered care; Quality of life; Qualitative research; SHARED DECISION-MAKING; ADJUVANT CHEMOTHERAPY; UPFRONT SURGERY; BREAST-CANCER; OPEN-LABEL; GEMCITABINE; CARE; SURVIVAL; ROLES;
D O I
10.4251/wjgo.v14.i6.1175
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Neoadjuvant therapy (NT) has increasingly been utilized for patients with localized pancreatic ductal adenocarcinoma (PDAC). It is the recommended approach for borderline resectable (BR) and locally advanced (LA) cancers and an increasingly utilized option for potentially resectable (PR) disease. Despite its increased use, little research has focused on patient-centered metrics among patients undergoing NT, including patient experiences, preferences, and recommendations. A better understanding of all aspects of the patient experience during NT may identify opportunities to design interventions aimed at improving quality of life; it may also facilitate the completion of NT and receipt of surgery, ultimately optimizing long-term outcomes. AIM To understand the experience of patients initiating and receiving NT to identify opportunities to improve neoadjuvant cancer care delivery. METHODS Semi-structured interviews of patients with localized PDAC during NT were conducted to explore their experience initiating and receiving NT. Interviews took place between August 2020 and October 2021. Due to the descriptive nature of the research, questions were open ended. Interviews were conducted over the phone, audio recorded and then transcribed. All interviews were coded by two independent researchers using NVivo 12, iteratively identifying themes until thematic saturation was achieved. An integrative approach to qualitative analysis was used, utilizing both inductive and deductive methods. RESULTS A total of 12 patients with localized PDAC were interviewed. Patients with BR (n = 7), PR (n = 2), and LA (n = 3) cancers participated in the study. All patients indicated that choosing NT was the doctor's recommendation, while most reported not being familiar with the concept of NT (n = 11) and that NT was presented as the only option (n = 8). Five themes describing the patient experience emerged: physical symptoms, emotional symptoms, coping mechanisms, access to care, and life factors. The most commonly cited recommendation for improving the experience of NT was improved education before and during NT (n = 7). Patients highlighted the need for more information on the rationale behind choosing NT prior to surgery, the anticipated surgery and its likelihood of surgery occurring after NT, as well as general information prior to starting NT treatment. The need for seeing different members of the healthcare team, including ancillary services was also frequently cited as a recommendation for improving the experience of NT (n = 5). CONCLUSION This study provides a framework to allow for a better understanding of the PDAC patient experience during NT and highlights opportunities to improve quality and quantity of life outcomes.
引用
收藏
页码:1175 / 1186
页数:12
相关论文
共 41 条
  • [1] Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement
    Abrams, Ross A.
    Lowy, Andrew M.
    O'Reilly, Eileen M.
    Wolff, Robert A.
    Picozzi, Vincent J.
    Pisters, Peter W. T.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) : 1751 - 1756
  • [2] National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016
    Aquina, Christopher T.
    Ejaz, Aslam
    Tsung, Allan
    Pawlik, Timothy M.
    Cloyd, Jordan M.
    [J]. JAMA NETWORK OPEN, 2021, 4 (03)
  • [3] Neoadjuvant Therapy Is Associated With Improved Survival in Resectable Pancreatic Adenocarcinoma
    Artinyan, Avo
    Anaya, Daniel A.
    McKenzie, Shaun
    Ellenhorn, Joshua D. I.
    Kim, Joseph
    [J]. CANCER, 2011, 117 (10) : 2044 - 2049
  • [4] Exploring patient experiences of neo-adjuvant chemotherapy for breast cancer
    Beaver, Kinta
    Williamson, Susan
    Briggs, Jean
    [J]. EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2016, 20 : 77 - 86
  • [5] Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes
    Beesley, Vanessa L.
    Janda, Monika
    Burmeister, Elizabeth A.
    Goldstein, David
    Gooden, Helen
    Merrett, Neil D.
    O'Connell, Dianne L.
    Wyld, David K.
    Chan, Raymond J.
    Young, Jane M.
    Neale, Rachel E.
    [J]. PALLIATIVE & SUPPORTIVE CARE, 2018, 16 (05) : 534 - 543
  • [6] Qualitative data analysis for health services research: Developing taxonomy, themes, and theory
    Bradley, Elizabeth H.
    Curry, Leslie A.
    Devers, Kelly J.
    [J]. HEALTH SERVICES RESEARCH, 2007, 42 (04) : 1758 - 1772
  • [7] Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma
    Brown, Zachary J.
    Cloyd, Jordan M.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2021, 123 (06) : 1432 - 1440
  • [8] Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy
    Christians, Kathleen K.
    Heimler, Jonathan W.
    George, Ben
    Ritch, Paul S.
    Erickson, Beth A.
    Johnston, Fabian
    Tolat, Parag P.
    Foley, William D.
    Evans, Douglas B.
    Tsai, Susan
    [J]. SURGERY, 2016, 159 (03) : 893 - 900
  • [9] Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol
    Cloyd, Jordan M.
    Hyman, Sarah
    Huwig, Tanya
    Monsour, Christina
    Santry, Heena
    Wills, Celia
    Tsung, Allan
    Bridges, John F. P.
    [J]. SUPPORTIVE CARE IN CANCER, 2021, 29 (06) : 3009 - 3016
  • [10] Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma
    Cloyd, Jordan M.
    Shen, Chengli
    Santry, Heena
    Bridges, John
    Dillhoff, Mary
    Ejaz, Aslam
    Pawlik, Timothy M.
    Tsung, Allan
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (05): : 556 - +